GlassScriptPhysician profile
Bernard W Douglas
NPI 1417062399
$6,154.20
in general payments reported to CMS, 2019-2025
33 companies · $935 in 2025
The $935 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $530 · 2021: $819 · 2022: $1,031 · 2023: $872 · 2024: $1,339 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,145.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $895.08 | 2021-2025 | Dupixent |
| Csl Behring | $888.38 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $734.13 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $587.50 | 2019-2025 | Fasenra |
| Pharming Healthcare, INC. | $479.23 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $469.08 | 2020-2025 | Takhzyro, Eohilia, Gattex |
| Genentech USA, INC. | $319.02 | 2023-2025 | Xolair |
| Biocryst US Sales Co., LLC | $305.10 | 2021-2025 | Orladeyo |
| Amgen INC. | $225.32 | 2021-2025 | Tezspire |
| Kaleo, INC. | $164.36 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $104.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $99.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.55 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $93.27 | 2019-2023 | Airduo Digihaler |
| Incyte Corporation | $83.18 | 2022-2024 | Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $74.72 | 2019-2022 | |
| Blueprint Medicines Corporation | $71.19 | 2024-2025 | Ayvakit |
| Octapharma USA, INC. | $63.92 | 2022-2024 | Octagam Immune Globulin (Human), Panzyga |
| Ars Pharmaceuticals Operations, INC. | $57.81 | 2025 | Neffy |
| Shire North American Group INC | $47.00 | 2019 | |
| Seqirus USA INC | $46.38 | 2021-2025 | Flucelvax |
| Jazz Pharmaceuticals INC. | $38.28 | 2019 | |
| Lilly USA, LLC | $36.43 | 2025 | Ebglyss |
| Optinose US, INC. | $27.91 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $24.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.45 | 2024 | |
| Genzyme Corporation | $16.51 | 2022 | |
| Hologic Sales and Service, LLC | $16.23 | 2019 | |
| Organon LLC | $15.02 | 2025 | Vtama |
| Ultragenyx Pharmaceutical INC. | $14.93 | 2021 | |
| Pfizer INC. | $14.89 | 2022 | |
| Ionis Pharmaceuticals, INC. | $14.74 | 2025 | Dawnzera |
| Ironshore Pharmaceuticals INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.